|
Cancer cells can progress to tumors after escaping the attack from normal T cells. By combining an antibody recognition domain with a T cell antigen receptor signaling motif, a more robust chimeric T cell antigen receptor is formed. This receptor not only has the superior tumor recognition capability, but also the ability to trigger T cell cytotoxicity effect. The genetically engineered T cells are usually referred to as the chimeric antigen receptor T cells or CAR-Ts. CAR-T cell therapy development is a complicated process that integrates several key technologies from early stage development to manufacturing. Each step requires robust and controlled methodology, operation, and strict quality control. CAR-T therapy, as an immunotherapeutic approach, shows less toxicity and risks than conventional radiotherapy or chemotherapy. Based on advanced technologies and years of researches, Creative Biolabs offers high-quality custom services that cover the entire CAR-T therapy development process to best suit your program and budget requirements, as well as to assist your research, preclinical investigation, and clinical stage development. |
